SFXN2 and Miyoshi myopathy: In addition, we analyzed MMREF CoMMpass datasets of newly RNA-seq over the course of MM, and found that SFXN2 could be inferred as a proxy of cancer progression from lower to higher aggressivity (Fig. 1d), indicating that exceptionally elevated SFXN2 might predict poor clinical outcomes of MM patients.